Wen, Di | Search NASA

DOE OSTI2024

High-quality Extragalactic Legacy-field Monitoring (HELM) with DECam

High-quality Extragalactic Legacy-field Monitoring (HELM) is a long-term observing program that photometrically monitors several well-studied extragalactic legacy fields with the Dark Energy Camera (DECam) imager on the CTIO 4m Blanco telescope. Since Feb 2019, HELM has been monitoring regions within COSMOS, XMM-LSS, CDF-S, S-CVZ, ELAIS-S1, and SDSS Stripe 82 with few-day cadences in the $(u)gri(z)$ bands, over a collective sky area of $\sim 38$ deg${\rm ^2}$. The main science goal of HELM is to provide high-quality optical light curves for a large sample of active galactic nuclei (AGNs), and to build decades-long time baselines when combining past and future optical light curves in these legacy fields. These optical images and light curves will facilitate the measurements of AGN reverberation mapping lags, as well as studies of AGN variability and its dependences on accretion properties. In addition, the time-resolved and coadded DECam photometry will enable a broad range of science applications from galaxy evolution to time-domain science. We describe the design and implementation of the program and present the first data release that includes source catalogs and the first $\sim 3.5$ years of light curves during 2019A--2022A.

79 ASTRONOMY AND ASTROPHYSICS↗

DOE OSTI2021

Bioorthogonal catalytic patch

The toxicity and complicated administration procedures of transition metal catalysts have hampered the applications of bioorthogonal catalysis in vivo. Here the authors fill the needles of a microneedle array patch with palladium nanoparticles deposited on titanium nanosheets and show that the device, applied locally on the skin of mouse models bearing melanoma, promotes intratumoural conversion of systemically injected caged doxorubicin into the active drug, reducing its toxicity and side effects. Bioorthogonal catalysis mediated by transition metals has inspired a new subfield of artificial chemistry complementary to enzymatic reactions, enabling the selective labelling of biomolecules or in situ synthesis of bioactive agents via non-natural processes. However, the effective deployment of bioorthogonal catalysis in vivo remains challenging, mired by the safety concerns of metal toxicity or complicated procedures to administer catalysts. Here, we describe a bioorthogonal catalytic device comprising a microneedle array patch integrated with Pd nanoparticles deposited on TiO 2 nanosheets. This device is robust and removable, and can mediate the local conversion of caged substrates into their active states in high-level living systems. In particular, we show that such a patch can promote the activation of a prodrug at subcutaneous tumour sites, restoring its parent drug's therapeutic anticancer properties. Finally, this in situ applied device potentiates local treatment efficacy and eliminates off-target prodrug activation and dose-dependent side effects in healthy organs or distant tissues.

77 NANOSCIENCE AND NANOTECHNOLOGY↗